MX2020010104A - Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado. - Google Patents
Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado.Info
- Publication number
- MX2020010104A MX2020010104A MX2020010104A MX2020010104A MX2020010104A MX 2020010104 A MX2020010104 A MX 2020010104A MX 2020010104 A MX2020010104 A MX 2020010104A MX 2020010104 A MX2020010104 A MX 2020010104A MX 2020010104 A MX2020010104 A MX 2020010104A
- Authority
- MX
- Mexico
- Prior art keywords
- psma
- drug conjugates
- antibody drug
- prostate
- specific membrane
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/884—Vaccine for a specifically defined cancer prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
La invención se refiere a anticuerpos humanizados de antígeno de membrana específico de próstata (anti-PSMA) y conjugados de anticuerpo anti-PSMA-fármaco. La invención también se refiere a métodos y composiciones para usar los conjugados de anticuerpo anti-PSMA-fármaco en inhibir, prevenir o tratar enfermedades o cánceres relacionados con PSMA.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862650277P | 2018-03-29 | 2018-03-29 | |
PCT/US2019/025057 WO2019191728A1 (en) | 2018-03-29 | 2019-03-29 | Humanized anti-prostate-specific membrane antigen (psma) antibody drug conjugates |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020010104A true MX2020010104A (es) | 2020-11-06 |
Family
ID=66103056
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020010104A MX2020010104A (es) | 2018-03-29 | 2019-03-29 | Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20210015940A1 (es) |
EP (1) | EP3773910A1 (es) |
JP (1) | JP2021519076A (es) |
KR (1) | KR20200138759A (es) |
CN (1) | CN111989138B (es) |
AU (1) | AU2019245444A1 (es) |
BR (1) | BR112020019611A2 (es) |
CA (1) | CA3094985A1 (es) |
IL (1) | IL277357A (es) |
MX (1) | MX2020010104A (es) |
SG (1) | SG11202009670RA (es) |
WO (1) | WO2019191728A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4041213A4 (en) * | 2019-10-29 | 2023-12-27 | The Cleveland Clinic Foundation | CONTRAST AGENTS DIRECTED AGAINST PSMA |
CN114929286A (zh) * | 2020-01-06 | 2022-08-19 | 西托姆克斯治疗公司 | 抗slc34a2抗体、抗体药物缀合物及它们的使用方法 |
US20230374150A1 (en) * | 2020-10-12 | 2023-11-23 | Memorial Sloan Kettering Cancer Center | Anti-psma antibodies and uses thereof |
WO2024077277A1 (en) | 2022-10-07 | 2024-04-11 | Ambrx, Inc. | Drug linkers and antibody conjugates thereof |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2504010B1 (fr) | 1981-04-15 | 1985-10-25 | Sanofi Sa | Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation |
US4542225A (en) | 1984-08-29 | 1985-09-17 | Dana-Farber Cancer Institute, Inc. | Acid-cleavable compound |
US4659839A (en) | 1984-10-10 | 1987-04-21 | Mallinckrodt, Inc. | Coupling agents for radiolabeled antibody fragments |
ATE66469T1 (de) | 1985-01-14 | 1991-09-15 | Neorx Corp | Metall-radionuklid markiertes protein fuer diagnose und therapie. |
US4680338A (en) | 1985-10-17 | 1987-07-14 | Immunomedics, Inc. | Bifunctional linker |
US4699784A (en) | 1986-02-25 | 1987-10-13 | Center For Molecular Medicine & Immunology | Tumoricidal methotrexate-antibody conjugate |
US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
US6107090A (en) * | 1996-05-06 | 2000-08-22 | Cornell Research Foundation, Inc. | Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains |
US6451986B1 (en) | 1998-06-22 | 2002-09-17 | Immunex Corporation | Site specific protein modification |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
AU2005211362B2 (en) | 2004-02-02 | 2008-03-13 | Ambrx, Inc. | Modified human interferon polypeptides and their uses |
ES2545533T3 (es) | 2004-11-01 | 2015-09-11 | The Regents Of The University Of California | Composiciones y métodos para modificación de biomoléculas |
AU2015203742B2 (en) * | 2007-06-26 | 2016-12-01 | The Johns Hopkins University | Labeled inhibitors of prostate specific membrane antigen (psma), biological evaluation, and use as imaging agents |
US10138283B2 (en) | 2008-07-23 | 2018-11-27 | Ambrx, Inc. | Modified bovine G-CSF polypeptides and their uses |
MX359217B (es) | 2011-05-27 | 2018-09-19 | Ambrx Inc | Composiciones que contienen, métodos que involucran, y usos de derivados de dolastatina unidos a aminoácidos no naturales. |
SG11201408153YA (en) | 2012-06-07 | 2015-01-29 | Ambrx Inc | Prostate-specific membrane antigen antibody drug conjugates |
CN104619350A (zh) * | 2012-06-14 | 2015-05-13 | Ambrx公司 | 结合到核受体配体多肽的抗psma抗体 |
US9388222B2 (en) * | 2013-10-06 | 2016-07-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modified Pseudomonas exotoxin A |
EP3464379B1 (en) * | 2016-06-06 | 2023-09-27 | Abzena (UK) Limited | Antibodies, uses thereof and conjugates thereof |
GB201614162D0 (en) * | 2016-08-18 | 2016-10-05 | Polytherics Ltd | Antibodies, uses thereof and conjugates thereof |
CN117286182A (zh) | 2017-06-02 | 2023-12-26 | Ambrx公司 | 促进含非天然氨基酸的蛋白质产生的方法和组合物 |
-
2019
- 2019-03-29 BR BR112020019611-8A patent/BR112020019611A2/pt unknown
- 2019-03-29 JP JP2020551572A patent/JP2021519076A/ja active Pending
- 2019-03-29 CA CA3094985A patent/CA3094985A1/en active Pending
- 2019-03-29 KR KR1020207030091A patent/KR20200138759A/ko unknown
- 2019-03-29 EP EP19717173.9A patent/EP3773910A1/en active Pending
- 2019-03-29 SG SG11202009670RA patent/SG11202009670RA/en unknown
- 2019-03-29 MX MX2020010104A patent/MX2020010104A/es unknown
- 2019-03-29 US US17/042,838 patent/US20210015940A1/en active Pending
- 2019-03-29 AU AU2019245444A patent/AU2019245444A1/en active Pending
- 2019-03-29 WO PCT/US2019/025057 patent/WO2019191728A1/en unknown
- 2019-03-29 CN CN201980025915.9A patent/CN111989138B/zh active Active
-
2020
- 2020-09-15 IL IL277357A patent/IL277357A/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2019245444A1 (en) | 2020-10-01 |
KR20200138759A (ko) | 2020-12-10 |
WO2019191728A1 (en) | 2019-10-03 |
CN111989138B (zh) | 2024-02-09 |
JP2021519076A (ja) | 2021-08-10 |
BR112020019611A2 (pt) | 2021-01-05 |
CA3094985A1 (en) | 2019-10-03 |
SG11202009670RA (en) | 2020-10-29 |
US20210015940A1 (en) | 2021-01-21 |
IL277357A (en) | 2020-11-30 |
EP3773910A1 (en) | 2021-02-17 |
CN111989138A (zh) | 2020-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018500815A1 (en) | Antibody conjugates comprising toll-like receptor agonist | |
PH12018501554A1 (en) | Ror1 antibody compositions and related methods | |
PH12020550860A1 (en) | Anti-trem2 antibodies and related methods | |
WO2018098306A8 (en) | Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies | |
AU2018253589A1 (en) | Antibodies, pharmaceutical compositions and uses thereof | |
MX2020010104A (es) | Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado. | |
NZ753515A (en) | Methods for treatment of cancer comprising tigit-binding agents | |
MX2019012811A (es) | Conjugados de anticuerpos que comprenden agonista del receptor de tipo toll y terapias de combinacion. | |
PH12017500890A1 (en) | Antibody drug conjugates | |
PH12018500380A1 (en) | Anti-dll3 antibody drug conjugates and methods of use | |
MX2022011732A (es) | Conjugados de farmacos y anticuerpos anti-ccr7. | |
MX2021015888A (es) | Fusión de un anticuerpo que se une a cea y 4-1bbl. | |
MX2018006249A (es) | Nuevos anticuerpos anti-emr2 y metodos de uso. | |
MX2021011750A (es) | Anticuerpos anti-egfrviii y fragmentos de union a antigenos de los mismos. | |
ZA202008095B (en) | Humanized antibodies against psma | |
MX2021007235A (es) | Tubulisinas y conjugados de proteina-tubulisina. | |
ZA202206993B (en) | Anti-lilrb1 antibody and uses thereof | |
PH12020551556A1 (en) | Drug conjugates of cmet monoclonal binding agents, and uses thereof | |
MX2018007817A (es) | Nuevos anticuerpos anti-mmp16 y metodos para su uso. | |
PH12020551968A1 (en) | Anti-sez6 antibody drug conjugates and methods of use | |
EA202090791A1 (ru) | Агонистические антитела против cd40 | |
MX2018013484A (es) | Nuevos anticuerpos anti-tnfrsf21 y modos de uso. | |
MX2018007818A (es) | Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso. | |
MX2021003756A (es) | Composiciones farmaceuticas que comprenden anticuerpos anti cumulo de diferenciacion 37 (cd37) biespecificos. | |
EA202192173A1 (ru) | Анти-cd228 антитела и конъюгаты антитело-лекарственное средство |